{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:30:53Z","timestamp":1794360653691,"version":"4.9.0"},"reference-count":40,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Muscular Dystrophy UK","award":["22GRO-PG24-0598-1"],"award-info":[{"award-number":["22GRO-PG24-0598-1"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glucocorticosteroids (GC) are standard-of-care treatment for most boys with duchenne muscular dystrophy (DMD). GC use has changed over time with evolving evidence, and we describe GC patterns, dosing and side-effects in the UK over 11 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>NorthStar data from 2012 to 2022 were analysed to understand GC type, regime and starting age. GC dose with age, patterns of GC switching and side-effect profiles by type and regime were also analysed. Participants attributed to \u2018other\u2019 regimes were queried and details were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data on GC usage were available for 1117 boys, across 6905 observations, with 74% of boys GC treated. Prednisolone was the most common regime in the period (65% of assessments) but deflazacort prescription has increased (17% in 2012 and 43% in 2022). Daily regimes were more common (66% of assessments), and the incidence of intermittent (10 days on\/10 days off) regimes has declined (46% in 2012 and 26% in 2022). Older participants were more commonly on less than recommended doses, and this was more common in those on deflazacort or daily regimes. Gastrointestinal symptoms and cushingoid features were more common in those on deflazacort than prednisolone, while increased appetite, cushingoid features, gastrointestinal symptoms and insomnia were more common in those on daily than intermittent regimes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The use of deflazacort and daily regimes has steadily increased across the UK North Star Network in the last decade. This study provides one of the largest up-to-date real-world set of data of evolution in prescription patterns and the occurrence of side-effects in different groups of GC-treated DMD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnnp-2024-335223","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:30:50Z","timestamp":1739367050000},"page":"794-801","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Observational study of changes to glucocorticosteroid prescribing patterns in duchenne muscular dystrophy in the UK over the last decade"],"prefix":"10.1136","volume":"96","author":[{"given":"Gregory","family":"Landon","sequence":"first","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"},{"name":"Dubowitz Neuromuscular Centre, UCL GOS Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-9898","authenticated-orcid":false,"given":"Georgia","family":"Stimpson","sequence":"additional","affiliation":[{"name":"Dubowitz Neuromuscular Centre, UCL GOS Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[{"name":"John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sarkozy","sequence":"additional","affiliation":[{"name":"Dubowitz Neuromuscular Centre, UCL GOS Institute of Child Health, London, UK"},{"name":"Great Ormond Street Hospital for Children, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y","family":"Manzur","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"},{"name":"Dubowitz Neuromuscular Centre, UCL GOS Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"UK NorthStar Clinical Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"},{"name":"Dubowitz Neuromuscular Centre, UCL GOS Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"},{"name":"Dubowitz Neuromuscular Centre, UCL GOS Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2025071606150588000_96.8.794.1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"2025071606150588000_96.8.794.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00585-4"},{"key":"2025071606150588000_96.8.794.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"2025071606150588000_96.8.794.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61897-2"},{"key":"2025071606150588000_96.8.794.5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(98)05279-9","article-title":"Failure of early diagnosis in symptomatic Duchenne muscular dystrophy","volume":"353","author":"Bushby","year":"1999","journal-title":"The Lancet"},{"key":"2025071606150588000_96.8.794.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.158329"},{"key":"2025071606150588000_96.8.794.7","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230159"},{"key":"2025071606150588000_96.8.794.8","doi-asserted-by":"crossref","unstructured":"Matthews E , Brassington R , Kuntzer T , et al . Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2023;2016. doi:10.1002\/14651858.CD003725.pub4","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"2025071606150588000_96.8.794.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07815-7"},{"key":"2025071606150588000_96.8.794.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-303902"},{"key":"2025071606150588000_96.8.794.11","first-page":"1709","article-title":"Ataluren: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025071606150588000_96.8.794.12","first-page":"329","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025071606150588000_96.8.794.13","first-page":"1027","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025071606150588000_96.8.794.14","first-page":"1699","article-title":"Eteplirsen: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025071606150588000_96.8.794.15","first-page":"1323","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025071606150588000_96.8.794.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1304-8"},{"key":"2025071606150588000_96.8.794.17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23831"},{"key":"2025071606150588000_96.8.794.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003217"},{"key":"2025071606150588000_96.8.794.19","doi-asserted-by":"crossref","unstructured":"Manzur AY , Kuntzer T , Pike M , et al . Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008. doi:10.1002\/14651858.CD003725.pub3","DOI":"10.1002\/14651858.CD003725.pub3"},{"key":"2025071606150588000_96.8.794.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001950"},{"key":"2025071606150588000_96.8.794.21","doi-asserted-by":"crossref","unstructured":"Pane M , Mazzone ES , Sivo S , et al . Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One 2014;9. doi:10.1371\/journal.pone.0108205","DOI":"10.1371\/journal.pone.0108205"},{"key":"2025071606150588000_96.8.794.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.4315"},{"key":"2025071606150588000_96.8.794.23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318227b164"},{"key":"2025071606150588000_96.8.794.24","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530180027012"},{"key":"2025071606150588000_96.8.794.25","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23272"},{"key":"2025071606150588000_96.8.794.26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpeds.2016.02.067","article-title":"Corticosteroid treatment and growth patterns in ambulatory males with duchenne muscular dystrophy","volume":"173","author":"Lamb","year":"2021","journal-title":"J Pediatr"},{"key":"2025071606150588000_96.8.794.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2018.01.017"},{"key":"2025071606150588000_96.8.794.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02158-9"},{"key":"2025071606150588000_96.8.794.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med"},{"key":"2025071606150588000_96.8.794.30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025071606150588000_96.8.794.31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"2025071606150588000_96.8.794.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309405"},{"key":"2025071606150588000_96.8.794.33","unstructured":"NICE . Equivalent anti-inflammatory doses of oral corticosteroids. CKS; 2020. Available: https:\/\/cks.nice.org.uk\/topics\/corticosteroids-oral\/background-information\/equivalent-anti-inflammatory-doses\/"},{"key":"2025071606150588000_96.8.794.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"2025071606150588000_96.8.794.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.09.005"},{"key":"2025071606150588000_96.8.794.36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","article-title":"Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database","volume":"76","author":"Joseph","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025071606150588000_96.8.794.37","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16415","article-title":"Relationship between growth and ambulation loss in Duchenne muscular dystrophy boys on steroids","volume":"31","author":"Stimpson","year":"2024","journal-title":"Eur J Neurol"},{"key":"2025071606150588000_96.8.794.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"2025071606150588000_96.8.794.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30026-7"},{"key":"2025071606150588000_96.8.794.40","unstructured":"National Institute of Health and Care Excellent . Vamorolone for treating duchenne muscular dystrophy. 2024."}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:15:54Z","timestamp":1752671754000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jnnp-2024-335223"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335223","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}